Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Change in Cash (2016 - 2025)

Coherus Oncology's Change in Cash history spans 13 years, with the latest figure at -$14.5 million for Q4 2025.

  • For Q4 2025, Change in Cash fell 151.15% year-over-year to -$14.5 million; the TTM value through Dec 2025 reached -$37.1 million, down 262.09%, while the annual FY2025 figure was -$37.1 million, 262.09% down from the prior year.
  • Change in Cash for Q4 2025 was -$14.5 million at Coherus Oncology, up from -$113.6 million in the prior quarter.
  • Across five years, Change in Cash topped out at $156.9 million in Q1 2024 and bottomed at -$281.7 million in Q1 2021.
  • The 5-year median for Change in Cash is -$3.6 million (2023), against an average of -$22.6 million.
  • The largest annual shift saw Change in Cash plummeted 1884.52% in 2021 before it surged 430.96% in 2024.
  • A 5-year view of Change in Cash shows it stood at $56.7 million in 2021, then crashed by 494.07% to -$223.3 million in 2022, then surged by 110.14% to $22.6 million in 2023, then rose by 25.03% to $28.3 million in 2024, then crashed by 151.15% to -$14.5 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Change in Cash are -$14.5 million (Q4 2025), -$113.6 million (Q3 2025), and $134.5 million (Q2 2025).